Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like cancer, there’s a lot of pressure to optimize these therapies. This is ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...

LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced new preclinical data from its lead program KLN-1010, which will be presented at ...

- "In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy" to be presented Friday, November 3, 2023, at 11:30 am PT PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma ...

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

PHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing ...

Researchers use in vivo chimeric antigen receptor (CAR) approaches to reprogram immune cells inside living systems, offering more efficient alternatives to traditional ex vivo CAR T development. 1 As ...